Catherine Novack
Stock Analyst at JonesTrading
(4.63)
# 894
Out of 5,004 analysts
125
Total ratings
41.1%
Success rate
23.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Catherine Novack
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Rated: Hold | n/a | $0.7755 | - | 7 | Jul 31, 2026 | |
| EQ Equillium | Rated: Hold | n/a | $1.67 | - | 5 | Jul 31, 2026 | |
| FEMY Femasys | Rated: Hold | n/a | $2.48 | - | 9 | Jul 31, 2026 | |
| CAPR Capricor Therapeutics | Downgraded: Hold | n/a | $8.36 | - | 10 | Jul 30, 2026 | |
| PRQR ProQR Therapeutics | Reiterated: Buy | $11 → $10 | $1.65 | +506.06% | 4 | Jun 26, 2026 | |
| SPRB Spruce Biosciences | Initiated Coverage: Buy | $135 | $48.81 | +176.58% | 1 | Jun 8, 2026 | |
| RZLT Rezolute | Reiterated: Buy | $6 | $3.90 | +53.85% | 8 | Jun 2, 2026 | |
| WVE Wave Life Sciences | Reiterated: Buy | $35 | $3.78 | +825.93% | 14 | May 19, 2026 | |
| IBIO iBio, Inc. | Reiterated: Buy | $7 | $1.19 | +488.24% | 2 | May 13, 2026 | |
| KRRO Korro Bio | Upgraded: Buy | $23 | $9.57 | +140.33% | 3 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $6.22 | +382.32% | 2 | Apr 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $16.62 | - | 10 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.405 | - | 4 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $13 | $3.08 | +322.76% | 9 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $143 → $209 | $138.16 | +51.27% | 7 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $43 | $37.77 | +13.85% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $33 | $5.06 | +552.17% | 1 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $9 | $1.21 | n/a | 14 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $16.03 | n/a | 1 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $1.75 | n/a | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $160 → $60 | $1.51 | n/a | 4 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $7.35 | n/a | 4 | Nov 15, 2021 |
Daré Bioscience
Jul 31, 2026
Rated: Hold
Price Target: n/a
Current: $0.7755
Upside: -
Equillium
Jul 31, 2026
Rated: Hold
Price Target: n/a
Current: $1.67
Upside: -
Femasys
Jul 31, 2026
Rated: Hold
Price Target: n/a
Current: $2.48
Upside: -
Capricor Therapeutics
Jul 30, 2026
Downgraded: Hold
Price Target: n/a
Current: $8.36
Upside: -
ProQR Therapeutics
Jun 26, 2026
Reiterated: Buy
Price Target: $11 → $10
Current: $1.65
Upside: +506.06%
Spruce Biosciences
Jun 8, 2026
Initiated Coverage: Buy
Price Target: $135
Current: $48.81
Upside: +176.58%
Rezolute
Jun 2, 2026
Reiterated: Buy
Price Target: $6
Current: $3.90
Upside: +53.85%
Wave Life Sciences
May 19, 2026
Reiterated: Buy
Price Target: $35
Current: $3.78
Upside: +825.93%
iBio, Inc.
May 13, 2026
Reiterated: Buy
Price Target: $7
Current: $1.19
Upside: +488.24%
Korro Bio
May 8, 2026
Upgraded: Buy
Price Target: $23
Current: $9.57
Upside: +140.33%
Apr 16, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $6.22
Upside: +382.32%
Apr 10, 2026
Rated: Hold
Price Target: n/a
Current: $16.62
Upside: -
Apr 10, 2026
Rated: Hold
Price Target: n/a
Current: $0.405
Upside: -
Feb 24, 2026
Reiterated: Buy
Price Target: $7 → $13
Current: $3.08
Upside: +322.76%
Feb 24, 2026
Reiterated: Buy
Price Target: $143 → $209
Current: $138.16
Upside: +51.27%
Dec 23, 2025
Initiated Coverage: Buy
Price Target: $43
Current: $37.77
Upside: +13.85%
Sep 30, 2025
Initiated Coverage: Buy
Price Target: $33
Current: $5.06
Upside: +552.17%
Aug 8, 2025
Reiterated: Buy
Price Target: $6 → $9
Current: $1.21
Upside: n/a
Jun 25, 2025
Initiated Coverage: Buy
Price Target: $30
Current: $16.03
Upside: n/a
Nov 15, 2024
Reiterated: Buy
Price Target: $15
Current: $1.75
Upside: n/a
Jun 3, 2024
Reiterated: Buy
Price Target: $160 → $60
Current: $1.51
Upside: n/a
Nov 15, 2021
Downgraded: Hold
Price Target: n/a
Current: $7.35
Upside: n/a